In vivo characterisation of 3-iodo-6-methoxybenzamide123I in humans

D. C. Costa, N. P.L.G. Verhoeff, I. D. Cullum, P. J. Ell, G. M.S. Syed, J. Barrett, E. Palazidou, B. Toone, E. Van Royen, M. Bobeldijk

Research output: Contribution to journalArticlepeer-review

76 Citations (Scopus)


3-Iodo-6-methoxybenzamide (123I-IBZM), a new Dopamine D2 receptor ligand, was used in conjunction with SME 810 brain tomography to study six subjects (one normal volunteer, four schizophrenics and one DAT patient). Initial Dynamic SPET was followed by multislice SPET. High-resolution images of the D2 receptor distribution in the basal ganglia were obtained. The specific binding in D2 receptors of the basal ganglia is highest from 2-4 h p.i. Patients on anti-psychotic drugs showed significantly lower specific binding. Dopamine D2 brain receptor availability in man may now be studied with SPET. Continuous data acquisition with single slice tomography is particularly important in the study of this type of radiotracers.

Original languageEnglish
Pages (from-to)813-816
Number of pages4
JournalEuropean Journal of Nuclear Medicine
Issue number11
Publication statusPublished - Nov 1990


  • I-IBZM
  • Dopamine D2
  • Dynamic SPET
  • Schizophrenia


Dive into the research topics of 'In vivo characterisation of 3-iodo-6-methoxybenzamide123I in humans'. Together they form a unique fingerprint.

Cite this